Market Cap 5.81M
Revenue (ttm) 0.00
Net Income (ttm) -34.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,700
Avg Vol 7,648
Day's Range N/A - N/A
Shares Out 950,000.00
Stochastic %K 29%
Beta 1.39
Analysts Strong Buy
Price Target $10.00

Company Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and t...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 837 3099
Address:
6 Liberty Square, Suite 2382, Boston, United States
Travelling
Travelling May. 21 at 2:19 PM
$SKLZ buying some to hold, watching $RNAZ $SBFM $WNW $PETZ
0 · Reply
Hovius
Hovius May. 20 at 12:28 PM
$RNAZ Looks like dilution machine is firing up, again.. Once trash, always trash.
0 · Reply
phantomtrader75
phantomtrader75 May. 20 at 5:20 AM
$RNAZ give us an update management!!!
0 · Reply
mbr60
mbr60 May. 19 at 6:05 PM
$RNAZ as usual because of the failiar administration
0 · Reply
Vedran1
Vedran1 May. 19 at 12:35 AM
$RNAZ Filled at 6.60. Was planning to move lower to 6.25 but my wife kept me on a leash with stuff in the house to do. Priorities... RNAZ should spike on "Phase 2a started" and "The first patient dosed" news.
0 · Reply
Scoty_D
Scoty_D May. 18 at 4:20 PM
$RNAZ Dr. Phillippe we believe in you bud! Execute that plan!
0 · Reply
Hovius
Hovius May. 18 at 4:18 PM
$RNAZ Any updates on Dr. Mordova and her presentation last Thursday? Sounds like something that investors might care about…
0 · Reply
Vedran1
Vedran1 May. 18 at 2:09 PM
$RNAZ Some own highlights from 10-Q re possible incoming news:
0 · Reply
Vedran1
Vedran1 May. 18 at 2:03 PM
$RNAZ Increased selling pressure last month or so. Will tray to add some at bid.
1 · Reply
mbr60
mbr60 May. 17 at 8:00 PM
0 · Reply
Latest News on RNAZ
TransCode Therapeutics Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 6 days ago

TransCode Therapeutics Quarterly report: Q1 2026


TransCode Therapeutics Proxy statement: Proxy filing

May 8, 2026, 8:00 AM EDT - 13 days ago

TransCode Therapeutics Proxy statement: Proxy filing


TransCode Therapeutics Annual report: Q4 2025

Apr 15, 2026, 7:00 AM EDT - 5 weeks ago

TransCode Therapeutics Annual report: Q4 2025


TransCode Therapeutics Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 6 weeks ago

TransCode Therapeutics Proxy statement: Proxy filing


TransCode Therapeutics Proxy statement: Proxy Filing

Mar 3, 2026, 7:00 AM EST - 2 months ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Dec 23, 2025, 7:00 AM EST - 5 months ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 6 months ago

TransCode Therapeutics Quarterly report: Q3 2025


TransCode Therapeutics Proxy statement: Proxy Filing

Oct 27, 2025, 8:00 AM EDT - 7 months ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Oct 17, 2025, 8:00 AM EDT - 7 months ago

TransCode Therapeutics Proxy statement: Proxy Filing


Transcode Therapeutics Inc trading resumes

2025-10-08T13:45:31.000Z - 8 months ago

Transcode Therapeutics Inc trading resumes


Transcode Therapeutics to acquire Polynoma

2025-10-08T12:16:56.000Z - 8 months ago

Transcode Therapeutics to acquire Polynoma


TransCode Therapeutics Proxy statement: Proxy Filing

Oct 8, 2025, 8:00 AM EDT - 8 months ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Oct 8, 2025, 8:00 AM EDT - 8 months ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Transcript: AGM 2025

Aug 29, 2025, 9:30 AM EDT - 9 months ago

TransCode Therapeutics Transcript: AGM 2025


TransCode Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

TransCode Therapeutics Quarterly report: Q2 2025


Transcode Therapeutics Inc trading resumes

2025-07-23T15:35:21.000Z - 10 months ago

Transcode Therapeutics Inc trading resumes


TransCode Therapeutics Proxy statement: Proxy Filing

Jul 15, 2025, 8:00 AM EDT - 11 months ago

TransCode Therapeutics Proxy statement: Proxy Filing


Transcode Therapeutics Inc trading halted, news pending

2025-05-14T23:50:13.000Z - 1 year ago

Transcode Therapeutics Inc trading halted, news pending


TransCode Therapeutics Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

TransCode Therapeutics Quarterly report: Q1 2025


TransCode Therapeutics Transcript: AGM 2025

May 2, 2025, 9:30 AM EDT - 1 year ago

TransCode Therapeutics Transcript: AGM 2025


TransCode Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Annual report: Q4 2024

Apr 17, 2025, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Annual report: Q4 2024


TransCode Therapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Apr 2, 2025, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Feb 4, 2025, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Dec 30, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Dec 19, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 5:00 PM EST - 1 year ago

TransCode Therapeutics Quarterly report: Q3 2024


TransCode Therapeutics Proxy statement: Proxy Filing

Nov 13, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Nov 6, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Oct 28, 2024, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Oct 15, 2024, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Jun 10, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Jun 7, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

May 20, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Open Letter to Shareholders

May 13, 2024, 8:30 AM EDT - 2 years ago

TransCode Therapeutics Open Letter to Shareholders


TransCode Therapeutics Proxy statement: Proxy Filing

May 13, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

May 10, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Earnings release: Q4 2023

Apr 3, 2024, 7:00 AM EDT - 2 years ago

TransCode Therapeutics Earnings release: Q4 2023


TransCode Therapeutics Annual report: Q4 2023

Apr 3, 2024, 7:00 AM EDT - 2 years ago

TransCode Therapeutics Annual report: Q4 2023


TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 11, 2024, 8:00 AM EST - 2 years ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split


TransCode Therapeutics Proxy statement: Proxy Filing

Jan 4, 2024, 7:00 AM EST - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Dec 18, 2023, 7:00 AM EST - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


TransCode Therapeutics Proxy statement: Proxy Filing

Dec 8, 2023, 7:00 AM EST - 2 years ago

TransCode Therapeutics Proxy statement: Proxy Filing


Travelling
Travelling May. 21 at 2:19 PM
$SKLZ buying some to hold, watching $RNAZ $SBFM $WNW $PETZ
0 · Reply
Hovius
Hovius May. 20 at 12:28 PM
$RNAZ Looks like dilution machine is firing up, again.. Once trash, always trash.
0 · Reply
phantomtrader75
phantomtrader75 May. 20 at 5:20 AM
$RNAZ give us an update management!!!
0 · Reply
mbr60
mbr60 May. 19 at 6:05 PM
$RNAZ as usual because of the failiar administration
0 · Reply
Vedran1
Vedran1 May. 19 at 12:35 AM
$RNAZ Filled at 6.60. Was planning to move lower to 6.25 but my wife kept me on a leash with stuff in the house to do. Priorities... RNAZ should spike on "Phase 2a started" and "The first patient dosed" news.
0 · Reply
Scoty_D
Scoty_D May. 18 at 4:20 PM
$RNAZ Dr. Phillippe we believe in you bud! Execute that plan!
0 · Reply
Hovius
Hovius May. 18 at 4:18 PM
$RNAZ Any updates on Dr. Mordova and her presentation last Thursday? Sounds like something that investors might care about…
0 · Reply
Vedran1
Vedran1 May. 18 at 2:09 PM
$RNAZ Some own highlights from 10-Q re possible incoming news:
0 · Reply
Vedran1
Vedran1 May. 18 at 2:03 PM
$RNAZ Increased selling pressure last month or so. Will tray to add some at bid.
1 · Reply
mbr60
mbr60 May. 17 at 8:00 PM
0 · Reply
Hovius
Hovius May. 16 at 1:17 AM
$RNAZ reading that fukin 10-Q is an absolute nightmare. Holy shit, all that money and they still have not produced anything of substance. Total garbage Mullen of medical world.
0 · Reply
Vedran1
Vedran1 May. 15 at 9:59 PM
$RNAZ Q report released today (did not read it yet): https://www.sec.gov/ix?doc=/Archives/edgar/data/0001829635/000110465926062535/rnaz-20260331x10q.htm
0 · Reply
Hovius
Hovius May. 15 at 7:59 PM
$RNAZ nice bait and switch, right at the end. Bad news incoming?
0 · Reply
phantomtrader75
phantomtrader75 May. 15 at 4:37 AM
$RNAZ The "20 Million Shares" is a Ceiling, Not a Dump The recent filing asks shareholders to approve the issuance of shares related to the $20 million Yorkville financing (SEPA). • Crucial Detail: Nasdaq rules currently cap them at issuing more than ~183,000 shares (19.9% of the float) until the shareholders officially vote "YES" at the upcoming Special Meeting. • The Opportunity: This means there is a "regulatory bottleneck." They physically cannot dump 20 million shares tomorrow morning. They have to wait for the meeting, which hasn't happened yet. This gives the "First Patient Dosed" news a clear runway to cause a squeeze before the big dilution can even start.
1 · Reply
Vedran1
Vedran1 May. 15 at 3:22 AM
$RNAZ I've unlocked this WSJ article so everyone can read this sad story here about melanoma, life and FDA: The FDA and My Daughter’s Death From Cancer - My family experienced the horror of malignant melanoma. Regulators have been blocking cures. https://www.wsj.com/opinion/the-fda-and-my-daughters-death-from-cancer-ed93ad71?st=8WcgNU&reflink=desktopwebshare_permalink
0 · Reply
phantomtrader75
phantomtrader75 May. 13 at 5:05 PM
$RNAZ God candle. Somebody just purchased over 20,000 shares.
1 · Reply
Hovius
Hovius May. 12 at 9:25 PM
$RNAZ For those of you who are skeptics and say that transcode therapeutics has never made anything substantial, I would just like to point out the hundreds of millions of shares they created… out of nothing..
1 · Reply
Vedran1
Vedran1 May. 12 at 7:29 PM
$RNAZ In WSJ today "FDA Commissioner Marty Makary, Under Pressure From Trump, to Leave Administration": "... Drug industry representatives pushed in recent weeks for a steady hand to lead the FDA. After Makary’s departure, John Crowley, president and chief executive of the Biotechnology Innovation Organization trade association, said: “What we need now is strong, stable and science-driven leadership at the FDA.” “We are losing the biotech race with China. FDA must be strengthened immediately,” Crowley added. ..."
0 · Reply
Hovius
Hovius May. 11 at 8:10 PM
$RNAZ Once trash.. always trash
0 · Reply
Nerdecus
Nerdecus May. 11 at 12:34 PM
$RNAZ trying to simplify some of the recent financing news/timeline: Apr 7: RNAZ announced up to $20M financing intended to extend runway into late 2027/early 2028. Apr 30: S-1 filed tied to convertible notes + SEPA/Yorkville structure. This can provide cash over time, but also creates potential dilution/share overhang. Apr 30: S-3 filed registering a decent number of resale shares. Important note: resale registration doesn’t automatically mean all shares hit the market immediately, but markets often react to the possibility. So overall: better cash/runway, but also dilution concerns. That’s a tightrope walk and the market tries to adjust to it.
0 · Reply
phantomtrader75
phantomtrader75 May. 9 at 9:22 PM
$RNAZ Chances of "Fast Track" for FDA Approval TransCode is already utilizing several FDA programs designed to accelerate the timeline from the lab to the patient.
3 · Reply
phantomtrader75
phantomtrader75 May. 9 at 9:21 PM
$RNAZ The Current Timeline Despite these accelerations, a "Fast Track" drug still requires rigorous testing. • Phase 2a (2026–2027): Proving the drug hits the target in humans. • Phase 3 (2027–2029): Confirming safety in a larger group. • Projected Market Entry: Even with aggressive "Fast Track" support, the earliest realistic window for FDA approval would be 2029 to 2030. The Bottom Line: TransCode is "skating to where the puck is going" by using the FDA's newest, fastest pathways. If the Phase 2a data is strong, the "Fast Track" becomes a "Green Light" for a major pharmaceutical buyout.
0 · Reply